Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method

A crystal form of (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, wherein the crystal form is crystal form A, hydrochloride crystal form I, hydrochloride crystal form II, maleate crystal form I, fumarate crystal form I, fumarate crystal form II, fumarate crystal form III, fumarate crystal form IV, fumarate crystal form V, L-tartrate crystal form I, succinate crystal form I or D-malate crystal form I, and the crystal form is characterized by an X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, wherein,

• the crystal form A has characteristic peaks at 14.2, 15.3, 16.1, 17.4, and 19.1;
• the hydrochloride crystal form I has characteristic peaks at 13.8, 15.9, 19.0, 20.1, and 22.8;
• the hydrochloride crystal form II has characteristic peaks at 13.2, 17.1, 19.7, 20.6, 22.8, and 25.0;
• the maleate crystal form I has characteristic peaks at 5.6, 8.8, 9.4, 10.2, 10.7, and 18.0;
• the fumarate crystal form I has characteristic peaks at 6.8, 9.6, 10.5, 17.6, 18.2, and 21.1;
• the fumarate crystal form II has characteristic peaks at 7.0, 9.4, 15.0, 17.1, 17.7, and 18.7;
• the fumarate crystal form III has characteristic peaks at 5.1, 9.6, 10.4, 17.9, 18.5, and 20.5;
• the fumarate crystal form IV has characteristic peaks at 6.2, 10.3, 11.1, 12.5, 21.3, and 22.2;
• the fumarate crystal form V has characteristic peaks at 10.5, 17.1, 18.6, 20.1, 21.0, and 23.7;
• the L-tartrate crystal form I has characteristic peaks at 9.1, 16.0, 17.7, 18.0, 20.0, and 20.7;
• the succinate crystal form I has characteristic peaks at 9.5, 16.0, 17.6, 18.0, 19.9, 20.7, and 22.3, and/or,
• the D-malate crystal form I has characteristic peaks at 9.0, 9.5, 10.7, 15.9, 17.9, 18.2, and 20.6;
• and the 2θ angles have a margin of error of 0.2.